Experts from Charles River and Valo Health describe how artificial intelligence will change the drug discovery landscape.
Category: biotech/medical – Page 798
Small interfering RNAs (siRNAs) are novel therapeutics that can be used to treat a wide range of diseases. This has led to a growing demand for selective, efficient, and safe ways of delivering siRNA in cells. Now, in a cooperation between the Universities of Amsterdam and Leiden, researchers have developed dedicated molecular nanocages for siRNA delivery. In a paper just out in the journal Chem they present nanocages that are easy to prepare and display tunable siRNA delivery characteristics.
The nanocages were developed in the research group for Homogeneous, Supramolecular and Bio-inspired catalysis of Prof. Joost Reek and Bas de Bruin at the University of Amsterdam’s Van ‘t Hoff Institute for Molecular Sciences, and further studies in the group Prof. Alexander Kros at the Leiden Institute of Chemistry.
The researchers were motivated by the potential of siRNA in gene therapy, which requires the need for effective delivery systems. They set out to develop nanocages with functional groups at the outside, making the cages capable of binding siRNA strands. As the binding is based on reversible bonds, the siRNA can in principle be released in a cellular environment. To explore the delivery characteristics of their nanocages, the researchers performed a laboratory study using various human cancer cells.
Among the biggest environmental problems of our time, micro-and nanoplastic particles (MNPs) can enter the body in various ways, including through food. And now for the first time, research conducted at MedUni Vienna has shown how these minute particles manage to breach the blood-brain barrier and as a consequence penetrate the brain. The newly discovered mechanism provides the basis for further research to protect humans and the environment.
Published in the journal Nanomaterials, the study was carried out in an animal model with oral administration of MNPs, in this case polystyrene, a widely-used plastic which is also found in food packaging. Led by Lukas Kenner (Department of Pathology at MedUni Vienna and Department of Laboratory Animal Pathology at Vetmeduni) and Oldamur Hollóczki (Department of Physical Chemistry, University of Debrecen, Hungary) the research team was able to determine that tiny polystyrene particles could be detected in the brain just two hours after ingestion.
The mechanism that enabled them to breach the blood-brain barrier was previously unknown to medical science. “With the help of computer models, we discovered that a certain surface structure (biomolecular corona) was crucial in enabling plastic particles to pass into the brain,” Oldamur Hollóczki explained.
Could a vaccine for dealing with cholesterol be in the works? If clinical trials succeed, Vaxxinity’s new vaccine could be a game changer for this chronic medical condition.
Millions daily take statins to combat high cholesterol. But a vaccine that turns on the body’s natural immune response is in the works.
To improve upon this technology, researchers created a souped-up MRI outfitted with a high-powered 9.4-tesla magnet. (For comparison, most MRIs are equipped with a 1.5-to 3-tesla magnet.) They also added gradient coils that are 100 times stronger than current models and are what create the images, as well as a high-speed computer that is as powerful as approximately 800 laptops, according to the statement.
After scanning the mouse brain, the researchers sent tissue samples to be imaged using a technique called light sheet microscopy, which allowed them to label specific groups of cells in the brain that were then mapped onto the original MRI. These additional steps provided a colorful view of cells and circuits throughout the brain, according to the statement.
The researchers took one set of MRI images that captured how the mouse’s brain-wide connectivity evolved with age. A second group of images showcased brilliantly colored brain connections that highlighted the deterioration of neural networks in a rodent model of Alzheimer’s disease, according to the statement.
Researchers repurpose tiny bacterial injection systems to specifically inject a wide variety of proteins into human cells and living mice.
Metabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease.
A new paper, published today in The Lancet by King’s College London and the Catholic University of Rome, is the first to compare three active treatments of non-alcoholic steatohepatitis (NASH) and to specifically investigate the effectiveness of metabolic surgery (weight loss surgery) in a randomized clinical trial.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, globally affecting 55% of people with type 2 diabetes and 75% of those with obesity. Non-alcoholic steatohepatitis (NASH) is the progressive form of the disease, and is characterized by liver cell injury and inflammation, which induce liver fibrosis (scarring of the tissue). Left untreated, it can lead to liver failure and liver cancer, and is one of the leading causes of liver transplant in the western world.
A stroke occurs when an artery in the brain becomes blocked or bursts. The brain cells beyond the blockage or bleed are deprived of oxygen and nutrients, so are damaged or die.
Scientists have been trying to find ways to minimize the damage following a stroke and speed up recovery.
Now, a study led by scientists from Weill Cornell Medicine has found changes in gene activity in small blood vessels following a stroke. The findings suggest that these changes could be targeted with existing or future drugs to mitigate brain injury or improve stroke recovery.
Autism spectrum disorder (ASD) is a developmental disorder associated with difficulties in interacting with others, repetitive behaviors, restricted interests and other symptoms that can impact academic or professional performance. People diagnosed with ASD can present varying symptoms that differ in both their behavioral manifestations and intensity.
As a result, some autistic individuals often require far more support than others to complete their studies, learn new skills and lead a fulfilling life. Neuroscientists have been investigating the high variability of ASD for several decades, with the hope that this will aid the development of more effective therapeutic strategies tailored around the unique experiences of different patients.
Researchers at Weill Cornell Medicine have recently used machine learning to investigate the molecular and neural mechanisms that could underlie these differences among individuals diagnosed with ASD. Their paper, published in Nature Neuroscience, identifies different subgroups of ASD associated with distinct functional connections in the brain and symptomatology, which could be related to the expression of different ASD-related genes.